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Objective: To perform two scoping systematic reviews of the literature on cytokine 
measurement in: 1. cerebral microdialysis (CMD) and 2. cerebrospinal fluid (CSF) in 
severe traumatic brain injury (TBI) patients.
Methods: Two separate systematic reviews were conducted: one for CMD cytokines 
and the second for CSF cytokines. Both were conducted in severe TBI (sTBI) patients 
only.
Data sources: Articles from MEDLINE, BIOSIS, EMBASE, Global Health, Scopus, 
Cochrane Library (inception to October 2016), reference lists of relevant articles, and 
gray literature were searched.
Study selection: Two reviewers independently identified all manuscripts utilizing pre-
defined inclusion/exclusion criteria. A two-tier filter of references was conducted.
Data extraction: Patient demographic and study data were extracted to tables.
Results: There were 19 studies identified describing the analysis of cytokines via CMD 
in 267 sTBI patients. Similarly, there were 32 studies identified describing the analysis 
of CSF cytokines in 1,363 sTBI patients. The two systematic reviews demonstrated: 
1. limited literature available on CMD cytokine measurement in sTBI, with some prelim-
inary data supporting feasibility of measurement and associations between cytokines 
and patient outcome. 2. Various CSF measured cytokines may be associated with 
patient outcome at 6–12 months, including interleukin (IL)-1b, IL-1ra, IL-6, IL-8, IL-10, 
and tumor necrosis factor 3. There is little to no literature in support of an association 
between CSF cytokines and neurophysiologic or tissue outcomes.
Conclusion: The evaluation of CMD and CSF cytokines is an emerging area of the 
literature in sTBI. Further, large prospective multicenter studies on cytokines in CMD and 
CSF need to be conducted.
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iNTRODUCTiON
Neuroinflammation after traumatic brain injury (TBI) is postu-
lated to be a key driver of secondary brain injury in the acute/
subacute phase after injury (1, 2). Upregulation of various 
components of the inflammatory cascade have been associated 
with lesion expansion (3), cerebral edema (4), derangements 
in neural transmission (5), and subsequent tissue death (6) in 
animal models of stroke and TBI. In humans, the inflamma-
tory process post-TBI has been of interest, since its therapeutic 
modulation can potentially lead to amelioration of pathophysiol-
ogy, tissue salvage, and improved patient outcomes (7, 8). Serum 
cytokine levels are easily measured in TBI patients, and elevation 
in pro-inflammatory cytokines have been associated with worse 
patient outcome (9, 10). However, systemic cytokine levels can 
be confounded by extracranial pathology and variable blood–
brain barrier leak of centrally derived mediators. Measurement 
of cerebral levels of cytokines provides a more direct metric of 
neuroinflammation following TBI, but, to date, the measurement 
of cerebral microdialysis (CMD) (11–29) and cerebrospinal fluid 
(CSF) (30–65) cytokines have been limited to small studies.
The goal of this study was to produce a scoping systematic 
review of the literature on both CMD and CSF cytokines in 
severe TBI (sTBI). Our hope was to produce a comprehensive 
overview of the literature on this emerging topic.
MeTHODS
Two separate scoping systematic reviews were conducted, using 
the methodology outlined in the Cochrane Handbook for 
Systematic Reviewers (66). Data were reported following the pre-
ferred reporting items for systematic reviews and meta-analyses 
(67). The review questions and search strategy were decided upon 
by the primary author (Frederick A. Zeiler) and supervisors (Adel 
Helmy and David K. Menon).
This manuscript was conducted in concert with a similar 
review on cytokines in CMD and CSF for aneurysmal subarach-
noid hemorrhage (SAH) patients.
Search Question and Population of 
interest
Given that two separate systematic reviews were conducted, 
one for CMD cytokines and the other for CSF cytokines, two 
distinct questions were posed. The limited literature on CMD 
cytokines identified through a preliminary search of PubMed 
led us to conduct a scoping review for the CMD cytokine search. 
We attempted to identify all studies in this area to date, and all 
articles describing microdialysis cytokine measures in humans 
with sTBI included in our review in order to provide a com-
prehensive overview of this emerging area of literature. The key 
question for this part of the review was:
•	 What literature has been published on CMD of cytokines in 
sTBI?
The larger literature base for CSF cytokines in TBI led us to 
narrow our question for this scoping review, focusing on relevant 
outcomes (see below). The questions posed for this scoping 
systematic review was:
•	 Is there literature to suggest an association between CSF cyto-
kine measures in sTBI and patient outcome, neurophysiologic 
outcome, or tissue outcome?
For the CSF cytokine review, the primary outcome meas-
ures were documented association between CSF cytokine 
levels and: patient outcome, neurophysiologic outcome (as 
measured via intensive care unit (ICU)-based monitoring; 
intracranial pressure (ICP)/cerebral perfusion pressure (CPP), 
brain tissue oxygen monitoring (PbtO2), thermal diffusion 
assessment of cerebral blood flow (CBF), transcranial Doppler 
(TCD) measure of cerebral blood flow velocity (CBFV), any 
neuroimaging based assessment of CBF/perfusion, and elec-
trophysiology), and tissue outcome [as assessed on follow-up 
neuroimaging by either computed tomography (CT) or mag-
netic resonance imaging]. Any outcome score or mention of 
morbidity/mortality within the studies was deemed acceptable 
for documentation of patient outcome. Secondary outcome 
measures were complications associated with CSF monitoring 
of cytokines.
The list of included cytokines in CMD or CSF included: 
interleukin (IL)-1a, IL-1b, IL-1ra, IL-2, sIL-2ra, IL-3, IL-4, IL-5, 
IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-12p70, IL-13, IL-14, 
IL-15, IL-16, IL-17, inducible protein (IP)-10, eotaxin, tumor 
necrosis factor (TNF), interferon gamma (INF-g), monocyte 
chemoattractant proteins, macrophage inflammatory proteins 
(MIPs), transforming growth factor (TGF), nerve growth factor 
(NGF), brain-derived neurotrophic factor, glial-derived neuro-
trophic factor, soluble tumor necrosis factor receptor (sTNFR), 
granulocyte macrophage colony stimulating factor, soluble FAS, 
soluble vascular cell adhesion molecule (sVCAM)-1, and soluble 
intracellular adhesion molecule (sICAM)-1, platelet-derived 
growth factor, regulated on activation, normal T cell expressed 
and secreted (RANTES), macrophage-derived chemokine 
(MDC), fms-like tyrosine kinase 3 (Flt3), Fractalkine, and fibro-
blast growth factor receptor.
inclusion/exclusion Criteria
CMD Cytokine Review
Inclusion criteria were: all studies including human subjects 
with sTBI (GCS 8 or less), any study size, any age category, CMD 
analysis for cytokines, and mention of any outcome (patient 
based or otherwise). Exclusion criteria were: non-English studies 
and animal studies.
CSF Cytokine Review
Inclusion criteria were: all studies including human subjects with 
sTBI (GCS of 8 or less), studies with 10 or more patients, any age 
category, CSF analysis for cytokines, and documentation either: 
patient functional outcome, neurophysiologic outcome, or tissue 
outcome in relation to CSF cytokine measures. Exclusion criteria 
were: non-English studies, animal studies, and studies of less than 
10 patients. Non-English studies were excluded given the small 
number identified.
Search Strategies
MEDLINE, BIOSIS, EMBASE, Global Health, SCOPUS, and 
Cochrane Library from inception to October 2016 were searched 
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using individualized search strategies. The search strategy for the 
CMD scoping systematic review using MEDLINE can be seen 
in Appendix A in Supplementary Material, with a similar search 
strategy utilized for the other databases. Further, the search strat-
egy for the CSF scoping systematic review using MEDLINE can 
be seen in Appendix B in Supplementary Material, with similar 
strategies employed for the other databases.
In addition, we surveyed relevant meeting proceedings 
for the last 5 years looking for ongoing and unpublished work 
based on cytokine analysis via CMD or CSF in sTBI patients. 
The meeting proceedings of the following professional societies 
were searched: Canadian Neurological Sciences Federation, 
American Association of Neurological Surgeons, Congress of 
Neurological Surgeons, European Neurosurgical Society, World 
Federation of Neurological Surgeons, National Neurotrauma 
Society, American Neurology Association, American Academy 
of Neurology, European Federation of Neurological Science, 
World Congress of Neurology, Society of Critical Care Medicine, 
Neurocritical Care Society, European Society for Intensive 
Care Medicine, World Federation of Societies of Intensive and 
Critical Care Medicine, American Society for Anesthesiologists, 
World Federation of Societies of Anesthesiologist, Australian 
Society of Anesthesiologists, International Anesthesia Research 
Society, Society of Neurosurgical Anesthesiology and Critical 
Care, Society for Neuroscience in Anesthesiology and Critical 
Care, Japanese Society of Neuroanesthesia and Critical Care, 
International NeuroTrauma Society, International Brain Injury 
Association, and the College of Intensive Care Medicine Annual 
Scientific Meeting (CICMASM—Australia).
Finally, reference lists of any review articles on CSF or CMD 
cytokines were reviewed for any missed relevant studies.
Study Selection
Utilizing two reviewers, a two-step review of all articles returned 
by our search strategies was performed. First, the reviewers inde-
pendently (Frederick A. Zeiler and Eric Peter Thelin) screened 
titles and abstracts of the returned articles to decide if they met 
the inclusion criteria. Second, full text of the chosen articles was 
then assessed to confirm if they met the inclusion criteria and 
that the primary outcomes of interest were reported in the study 
(Frederick A. Zeiler and Eric Peter Thelin). Any discrepancies 
between the two reviewers were resolved by a third reviewer if 
needed (Adel Helmy or David K. Menon).
Data Collection
Data were extracted from the selected articles and stored in an 
electronic database. Data fields included: patient demographics, 
type of study, article location, number of patients, CMD/CSF 
substrate measured, CMD/CSF measurement details (probe tis-
sue location, sampling frequency), outcome measure described 
(patient, neurophysiologic, tissue), association between CMD/
CSF cytokine measure to outcome, and complications. All 
extracted data can be found in Tables 1 through 4, with study 
designs in Tables 1 and 2, and study outcomes in Tables 3 and 4.
Bias Assessment
As the goal of this review was to produce a systematically con-
ducted scoping review of the available literature on CMD and 
CSF cytokine measures in sTBI, formal bias assessment was not 
done. Our desire was to produce a comprehensive overview of 
the current literature on the topic of CMD/CSF cytokines in 
sTBI. Formal evidence grading was not conducted (given the 
limited and heterogenous literature body), and thus we deemed 
formal bias risk assessment unnecessary for this emerging area 
of literature, which clearly suffers from standard biases associated 
with new areas of clinical research.
Statistical Analysis
A meta-analysis was not performed in this study due to the het-
erogeneity of data and study design within the articles identified.
ReSULTS
Search Strategy Results
CMD Cytokine Search
Results of the search strategy for CMD cytokines in sTBI is 
shown in the flow diagram in Figure 1. In total, 259 articles were 
identified, with 255 from the database and 4 from meeting pro-
ceeding sources. After removal of the duplicates, there were 144 
articles left for assessment in the first filter of title and abstract. 
Thirty-seven articles passed the first filter, requiring acquisition 
of the full manuscript to assess inclusion eligibility. After assess-
ing the full manuscripts, 19 articles were deemed eligible for 
final inclusion in the scoping systematic review. No articles were 
added from the reference sections of either review papers or the 
parent manuscripts included in the systematic review.
CSF Cytokine Search
The search strategy flow diagram for the CSF cytokine scoping 
systematic review is shown in Figure  2. Overall, 3,218 articles 
were identified, with 3,214 from the database search and 4 from 
published meeting proceedings. There were 1,317 duplicates 
removed, leaving 1,901 references to review in the first filter. 
Applying the inclusion/exclusion criteria to the title and abstract 
of these articles, 105 manuscripts were selected for review of the 
full article. One additional reference was added from the refer-
ence sections of review papers. During the second filter of the 
full manuscript, 36 met the final inclusion criteria for the scop-
ing systematic review. Remaining articles were excluded due to 
non-relevance.
Patient/Study Demographics
CDM Cytokine Review
Of the 19 articles included in the CMD cytokine portion of the 
systematic review (11–19), 15 were formal manuscript publica-
tions (14–24, 26–29) and 4 were meeting abstract publications 
(11–13, 25). There were 13 prospective studies (13–16, 18–21, 
25–29), with 12 prospective observational studies (13–15, 18–21, 
25–29) and 1 prospective randomized control trial (16). Four 
studies were retrospective case series or database reviews (11, 20, 
22, 23). Finally, two studies were of “unknown” study design given 
a lack of information available within the methods (12, 24).
The study population described in CMD cytokine papers was 
generally poorly characterized sTBI patient populations, under-
going various ICU and surgical therapies for their heterogeneous 
TABLe 1 | CMD cytokine study characteristics and patient demographics.
Reference Number of 
patients
Study type Article 
location
Mean age 
(years)
Patient 
characteristics
Primary and secondary goal of study
Cederberg et al. (11) 7 Retrospective 
case series
Meeting 
abstract
Unknown 
“children”
Severe TBI; 3 
underwent DC
Primary: to compare CMD cytokines to  
common CMD measures, PbtO2, and ICP
Secondary: none mentioned
Figaji et al. (12) 5 Unknown Meeting 
abstract
Unknown 
“children”
Severe TBI Primary: to compare CMD cytokine and other  
CMD measures
Secondary: none mentioned
Guilfoyle et al. (13) 12 Prospective 
observational
Meeting 
abstract
Unknown 
“adults”
Severe TBI Primary: to compared CMD cytokine  
measures in healthy vs. peri-lesional tissue
Secondary: none mentioned
aHelmy et al. (14) 12 Prospective 
observational
Manuscript Unknown 
“adults”
Severe TBI Primary: to perform a principle component  
analysis of CMD cytokines to determine  
cytokine patterns and temporal profiles
Secondary: none mentioned
aHelmy et al. (15) 12 Prospective 
observational
Manuscript Unknown 
“adults”
Severe TBI Primary: 1. To compare crystalloid vs. albumin 
perfusate in CMD cytokine recovery.  
2. To compare the cytokine profile in sTBI
Secondary: not specified
bHelmy et al. (16) 20 Prospective RCT Manuscript 38.9 years 
(range: 
18–61 years)
Severe diffuse 
TBI; randomized 
to subcutaneous 
rhIL-1ra
Primary: 1. To provide safety data in a  
randomized fashion on rhIL-1ra in sTBI
2. To describe the impact of rhIL-1ra on  
CMD cytokine profiles
Secondary: none mentioned
bHelmy et al. (17) 20 Retrospective 
database analysis
Manuscript 38.9 years 
(range: 
18–61 years)
Severe diffuse 
TBI; randomized 
to subcutaneous 
rhIL-1ra
Primary: to retrospectively analyze RCT data  
on rhIL-1ra administration, to better delineate  
the temporal change in cytokine profiles
Secondary: none mentioned
Hillman et al. (18) 9 (10 total, but 
failed CMD 
catheter in 1)
Prospective 
observational
Manuscript Unknown Severe brain injury 
(undisclosed 
number of aSAH 
and sTBI patients)
Primary: to evaluate newer microdialysis  
catheters and their ability to measure various 
CMD macromolecules (including IL-6) vs. older 
catheters. Varied perfusates were also analyzed
Secondary: none mentioned
Hillman et al. (19) 7 with TBI (14 
total; mixed 
injury sources)
Prospective 
observational
Manuscript Unknown sTBI—5  
requiring “surgery”
Primary: to determine the CMD cytokine  
patterns in TBI
Secondary: none mentioned
Hutchinson et al. (20) 15 Prospective 
observational
Manuscript 41 years 
(range: 
17–68 years)
Severe TBI Primary: to determine the feasibility of measures 
IL-1a, IL-1b, and IL-1ra in CMD samples
Secondary: correlation of cytokine to ICP, CPP,  
and patient outcome
Mellergard et al. (21) 7 (total 38 
patients; only  
7 with TBI)
Prospective 
observational
Manuscript Unknown Severe TBI Primary: to evaluate CMD cytokine profiles 
immediately after insertion of the CMD catheter
Secondary: none mentioned
cMellergard et al. (22) 57 (total 145 
patients; only 
57 with TBI)
Retrospective 
case series
Manuscript Unknown Severe TBI Primary: to determine the CMD cytokine  
responds to TBI
Secondary: none mentioned
cMellergard et al. (23) 57 (total 145 
patients; only 
57 with TBI)
Retrospective 
case series
Manuscript Unknown Severe TBI Primary: to determine the CMD cytokine  
responds to TBI
Secondary: none mentioned
Mellergard et al. (24) 69 Unknown Manuscript 45.9 years 
(range: 
unknown)
Severe TBI Primary: to determine if there is age-related 
difference in CMD cytokines
Secondary: none mentioned
Mondello et al. (25) 6 Prospective 
observational
Meeting 
abstract
Unknown Severe TBI Primary: to evaluate the temporal profile  
of CMD and CSF cytokines in TBI
Secondary: none mentioned
(Continued)
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Reference Number of 
patients
Study type Article 
location
Mean age 
(years)
Patient 
characteristics
Primary and secondary goal of study
Parez-Barcena  
et al. (26)
16 Prospective 
observational
Manuscript 31.8 years 
(range: 
16–65 years)
Severe diffuse TBI Primary: to determine the cytokine profiles  
in severe diffuse TBI patients
Secondary: to determine the correlation between 
cytokines and ICP, PbtO2, and CT changes
Roberts et al. (27) 8 Prospective 
observational
Manuscript 43.4 years 
(range: 
unknown)
Severe TBI Primary: to measure the blood/CSF/CMD MMP 
and cytokine response post-TBI
Secondary: correlation to neurologic exam, ICP, 
PbtO2, GOS at discharge
Winter et al. (28) 3 Prospective 
observational
Manuscript Unknown Severe TBI Primary: to describe the technique of cytokine 
measurement via CMD
Secondary: describe cytokine patterns in TBI
Winter et al. (29) 14 Prospective 
observational
Manuscript 43.1 years 
(range: 
21–77 years)
Severe TBI Primary: to evaluate the changes in CMD 
cytokines post-TBI
Secondary: correlation to patient outcome
TBI, traumatic brain injury; sTBI, severe TBI; aSAH, aneurysmal subarachnoid hemorrhage; DC, decompressive craniectomy; CMD, cerebral microdialysis; RCT, randomized control 
trial; ICP, intracranial pressure; CPP, cerebral perfusion pressure; CSF, cerebrospinal fluid; LPR, lactate:pyruvate ratio; CT, computed tomography; PbtO2, partial pressure of oxygen 
in brain tissue; MMPs, matrix metalloproteins, IL, interleukin; a, alpha; b, beta; ra, receptor anatogonist; rh, recombinant human.
aSame patient population reported in both Helmy et al. (14) and Helmy et al. (15).
bSame patient population described in Helmy et al. (16) and Helmy et al. (17).
cSame patient population reported in both Mellergard et al. (22) and Mellergard et al. (23).
TABLe 1 | Continued
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intracranial pathology (11–15, 18–25, 27–29). Three studies 
focused on only those patients with imaging defined “diffuse” 
brain injury, without extra-axial or large focal intraparenchymal 
lesions (16, 17, 26).
A total of 267 unique patients with sTBI were described across 
the 19 studies included in the CMD cytokine review. Thirty-six 
patients were “diffuse” sTBI only (16, 17, 26), with the remaining 
being unspecified heterogeneous sTBI pathology. We believe that 
some of the studies included within this portion of the review 
may contain duplicate patient information, as marked in Tables 1 
and 3. Multiple publications from the same research groups 
likely were conducted on the same patient populations, yielding 
unique and separate manuscripts on the same group of patients. 
Though we must acknowledge it was difficult to determine, in 
some circumstances, whether CMD cytokine analysis was being 
conducted on new patient groups or existing banked samples 
from previous prospective studies. With that said, our goal for 
the CMD cytokine scoping review was to provide an overview 
of all available literature in the area, hence we have included all 
published papers on CMD cytokines in sTBI within this review.
CSF Cytokine Review
Of the 36 articles included in the CSF cytokine systematic review 
(20–65), 32 were formal manuscript publications (30–36, 39, 40, 
42–61, 63–65) and 4 were meeting abstract publications (37, 38, 
41, 62). There were 34 prospective studies, all being observational 
studies (30–61, 64, 65). One study was a retrospective case series 
(63). Finally, one study had insufficient information to determine 
the design (62).
The populations described with in the CSF cytokine studies 
were almost all sTBI patients with unspecified heterogeneous 
injury patterns. Three studies documented the inclusion of both 
moderate-severe patients within the methods (39, 53, 62). We 
were unable to separate the moderate and sTBI patients within 
these studies, hence they were all included in the final descriptive 
statistics.
A total of 1,363 patients were described across all studies 
included in the CSF cytokine systematic review. The mean age for 
each study cohort varied significantly across studies. Twenty-one 
studies included pediatric patients within their studies, either as 
the primary population of interest or included with adult patients 
(31–35, 42, 44, 47–50, 52, 54, 55, 57, 59, 60, 63–65). Therapies 
received by these patients while in the ICU varied significantly, 
with profound heterogeneity in treatment provided. Details sur-
rounding patient cohort, study design, and concurrent therapies 
can be found in Tables 2 and 4. We made substantial efforts to 
exclude duplicate patient data across studies. However, given 
that many of the papers came from centers of excellence for 
TBI research, some of the patient data may be cross reported 
in multiple studies. This could reduce the total overall number 
of unique patients. It was impossible based on the information 
provided within the parent studies to tease out all patients which 
were reported more than once.
Cytokine Measurement Technique
CMD Cytokine Review
Location of the CMD catheter was the following: mixed healthy/
peri-lesional tissue in six studies (11, 13, 15, 21–23), peri-lesional 
in six studies (14, 16–19, 28), healthy tissue in two studies 
(27, 29), and unknown tissue location in five studies (12, 20, 
24–26). Some studies utilized paired microdialysis catheters, 
one in healthy and one in peri-lesional tissue (13, 15, 22, 23). 
One study evaluated two catheters in one location (18). Analysis 
interval for CMD samples was as follows: every 6 h in 12 studies 
(14–24, 27), every 8  h in 1 study (26), every 3  h in 2 studies 
(28, 29), and unspecified in 4 studies (11–13, 25). The duration 
TABLe 2 | CSF cytokine study characteristics and patient demographics.
Reference Number of 
patients
Study type Article 
location
Mean age  
(years)
Patient 
characteristics
Primary and secondary goal of study
Patient functional outcome
Abboud et al. (30) 31 Prospective 
observational
Manuscript 31.6 years (range: 
unknown)
Severe TBI Primary: to describe the correlation between CSF 
cytokine profiles and outcome at 6 and 12 months
Secondary: none mentioned
Bell et al. (31) 15 Prospective 
observational
Manuscript 6.1 years (range: 
0.1–16 years)
Severe TBI Primary: to determine the relationship between  
IL-6 and IL-10 with patient outcome
Secondary: to compare CSF cytokine levels to  
non-TBI control subjects (n = 20)
Chiaretti et al. (32) 29 Prospective 
observational
Manuscript 9.7 years (range: 
1.3–15.6 years)
Severe TBI Primary: to determine the association between  
IL-6 and patient outcome
Secondary: to determine the correlation between IL-6 
and NGF in CSF. Also to compare to non-TBI control 
patients (n = 31)
Chiaretti et al. (33) 27 Prospective 
observational
Manuscript 8.6 years (range: 
1.3–15.6)
Severe TBI Primary: to determine the association between IL-1b, 
IL-6, NGF, BDNF, and GDNF with patient outcome
Secondary: none mentioned
Chiaretti et al. (34) 14 Prospective 
observational
Manuscript 7.8 years (range: 
0.3–15.6 years)
Severe TBI Primary: to determine the relationship between  
IL-1b and IL-6 with patient outcome
Secondary: to compared cytokine expression  
to obstructive hydrocephalus controls
Hans et al. (35) 11 Prospective 
observational
Manuscript 36.7 years (range: 
16–67)
Severe TBI Primary: to determine the association between  
IL-6 and sIL-6R to patient outcome
Secondary: to compare these CSF cytokine  
levels to those in plasma
Hayakata et al. (36) 53 Prospective 
observational
Manuscript 34–49 years Severe TBI Primary: to determine the association between TNF-a, 
IL-1, IL-6, IL-8, and IL-10 with patient outcome
Secondary: to determine the association between 
cytokines and S100B expression in CSF. Also 
compare cytokines to ICP
Jamil et al. (37) 61 Prospective 
observational
Meeting 
abstract
Unknown “adults” Severe TBI Primary: to determine the relationship between  
acute measures of CSF cytokines and PTD at  
6 and 12 months
Secondary: none mentioned
Juengst et al. (38) 25 Prospective 
observational
Meeting 
abstract
Unknown “adults” Severe TBI Primary: to determine the association between  
acute cytokine levels and apathy at 6 and 12 months 
post-injury
Secondary: none mentioned
Juengst et al. (39) 37 Prospective 
observational
Manuscript “Adults” Moderate–severe 
TBI
Primary: to determine the relationship between  
TNF-a and disinhibition/suicidality post-TBI
Unclear overall 
mean age
Secondary: compare levels in CSF and serum to 
healthy controls (n = 15)
Juengst et al. (40) 50 Prospective 
observational
Manuscript 31.3 years (range: 
unknown)
Severe TBI Primary: to determine the relationship between acute 
CSF cytokine profiles and the risk of PTD at 6 and 
12 months post-injury
Secondary: none mentioned
Kirchhoff et al. (41) 23 Prospective 
observational
Meeting 
abstract
Unknown Severe TBI Primary: to determine the IL-10 response in CSF in TBI 
patients. Also determine the relationship to outcome.
Secondary: compared CSF in TBI to elective surgical 
patients (n = 10)
Kossmann et al. (42) 22 Prospective 
observational
Manuscript 41 years (range: 
17–73)
Severe TBI Primary: to determine the relationship between CSF 
IL-6 and NGF. Also determine the association to 
patient outcome.
Secondary: compare IL-6 and NGF in controls (n = 3)
(Continued)
6
Zeiler et al. CSF and Microdialysis Cytokines in TBI
Frontiers in Neurology | www.frontiersin.org July 2017 | Volume 8 | Article 331
Reference Number of 
patients
Study type Article 
location
Mean age  
(years)
Patient 
characteristics
Primary and secondary goal of study
Kumar et al. (43) 114 Prospective 
observational
Manuscript Unclear overall 
mean age
Severe TBI Primary: to determine the relationship of IL-6 in CSF to 
serum values and patient outcome
Secondary: compare CSF levels in non-TBI controls 
(n = 23)
Kumar et al. (44) 111 Prospective 
observational
Manuscript Unknown (range: 
16–75)
Severe TBI Primary: to utilize PCA to determine clusters of 
cytokines associated with patient outcome
Secondary: to determine a temporal patter of cytokine 
clusters and relationship to outcome
Kushi et al. (45) 22 Prospective 
observational
Manuscript 45 years (range: 
unknown)
Severe TBI Primary: to compare CSF and Serum IL-6/IL-8  
levels and determine the association to patient  
outcome
Secondary: none mentioned
Nwachuku et al. (46) 32 Prospective 
observational
Manuscript 31 years (range: 
unknown)
Severe TBI Primary: to determine the association between various 
CSF cytokines and patient outcome
Secondary: none mentioned
Santarseiri et al. (47) 91 Prospective 
observational
Manuscript 35.8 years (range: 
16–73)
Severe TBI Primary: to identify CSF cytokines associated with 
patient outcome. Also determine association  
between cytokines and neuroendocrine cortisol  
function
Secondary: none mentioned
Shiozaki et al. (48) 35 Prospective 
observational
Manuscript 39 years (range: 
14–77 years)
Severe TBI Primary: to determine the association between CSF 
cytokine profiles and patient outcome
Secondary: to determine the association between 
cytokines and ICP
Singhal et al. (49) 36 Prospective 
observational
Manuscript 34.4 years (range: 
17–68 years)
Severe TBI Primary: to determine the association between 
cytokines and electrophysiologic/functional patient 
outcome
Secondary: none mentioned
Whalen et al. (50) 27 Prospective 
observational
Manuscript Unknown “children” Severe TBI Primary: to determine the association between CSF 
IL-8 levels and patient outcome
Secondary: to determine the association between  
CSF IL-8 in TBI patients and non-TBI controls  
(n = 24)
Neurophysiologic association
Muller et al. (51) 25 Prospective 
observational
Manuscript 41 years (range: 
unknown)
Severe TBI Primary: to evaluate the relationship between CSF 
IL-6, IL-8, and IL-10 with TCD defined CBF
Secondary: none mentioned
Stein et al. (52) 14 with 
CSF 
cytokines
Prospective 
observational
Manuscript 31.6 years (range: 
unknown)
Severe TBI Primary: to determine the relationship between CSF 
cytokines with ICP and patient outcome
Secondary: none mentioned
Nil association studies
Amick et al. (53) 24 Prospective 
observational
Manuscript 5.4 years (range: 
0.2–16 years)
Moderate–severe 
TBI
Primary: to determine the association between IL-2, 
IL-4, IL-6 and IL-12 with patient outcome
Secondary: compare IL levels in CSF to non-TBI 
controls (n = 12)
Buttram et al. (54) 36 Prospective 
observational
Manuscript 6.9 years (range: 
unknown)
Severe TBI Primary: to measure CSF cytokines and determine 
the impact of moderate hypothermia on expression. 
Also determine the link between CSF cytokines and 
outcome
Secondary: compared CSF cytokine profile to non-TBI 
controls (n = 10)
Csuka et al. (55) 28 Prospective 
observational
Manuscript 36 years (range: 
16–67 years)
Severe TBI Primary: to determine the association between various 
CSF and serum cytokines
Secondary: to determine the association between CSF 
cytokines with outcome and ICP
(Continued)
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Reference Number of 
patients
Study type Article 
location
Mean age  
(years)
Patient 
characteristics
Primary and secondary goal of study
Diamond et al. (56) 59 with 
CSF 
cytokines
Prospective 
observational
Manuscript Unclear mean age 
for CSF cytokine 
cohort
Moderate–severe 
TBI
Primary: to determine the association between  
serum and CSF cytokine levels with the development  
of PTE
Secondary: to compare serum and CSF levels with 
healthy control values. Also assess genetic IL-1b 
associations with PTE
Goodman et al. (57) 23 Prospective 
observational
Manuscript 32.7 years (range: 
15–57 years)
Severe TBI Primary: to compare CSF and jugular venous cytokine 
profiles
Secondary: to compare cytokine profiles to ICP and 
CPP
Gopcevic et al. (58) 20 Prospective 
observational
Manuscript 53 years (range: 
unknown)
Severe TBI Primary: to determine the association between  
jugular serum and CSF IL-8 levels with in-hospital  
mortality
Secondary: to determine the association between 
jugular plasm and CSF IL-8 levels
Lenzlinger et al. (59) 41 Prospective 
observational
Manuscript 38 years (range: 
15–74 years)
Severe TBI Primary: to determine the association between CSF 
and serum cytokines with patient outcome
Secondary: to compared serum and CSF cytokine 
profiles
Maier et al. (60) 29 Prospective 
observational
Manuscript 54.8 years (range: 
16–85 years)
Severe TBI Primary: to determine the CSF profile for two soluble 
tumor necrosis factor receptors (TNFR’s)
Secondary: to determine the association between CSF 
sTNFR levels and patient outcome
Maier et al. (61) 29 Prospective 
observational
Manuscript 45.5 years (range: 
18–75 years)
Severe TBI Primary: to evaluate the correlation between CSF and 
serum cytokine
Secondary: to determine the association between 
cytokine profile and patient outcome. Also, compare 
to CSF from healthy volunteers (n = 35)
Morganti-Kossmann 
et al. (62)
42 Unclear Meeting 
abstract
Unknown Severe TBI with 
various primary 
and secondary 
injuries
Primary: to determine the association between serum 
and CSF cytokines with injury patterns
Secondary: to determine the association between 
cytokine profiles and patient outcome
Newell et al. (63) 66 Retrospective 
case series
Manuscript 6 years (range: 
0.1–16 years)
Severe TBI Primary: to measure inflammatory markers in the CSF 
linked to T-cell activation
Secondary: to comment on the association between 
these markers and patient outcome. Also compare 
levels to healthy controls
Ross et al. (64) 50 Prospective 
observational
Manuscript 21 years (range: 
4–70 years)
Severe TBI Primary: to compare serum and CSF TNF-a in TBI 
patients to healthy controls (n = 46)
Secondary: to compare TNF-a levels to patient 
outcome
Uzan et al. (65) 11 Prospective 
observational
Manuscript 28.5 years (range: 
2.5–53 years)
Severe TBI Primary: to determine the association between NO 
metabolic products and IL-8
Secondary: to determine the association between NO 
and IL-8 with patient outcome
TBI, traumatic brain injury; sTBI, severe TBI; RCT, randomized control trial; ICP, intracranial pressure; CPP, cerebral perfusion pressure; CSF, cerebrospinal fluid; CBF, cerebral blood 
flow; PbtO2, partial pressure of oxygen in brain tissue; TCD, transcranial Doppler; DC, decompressive craniectomy; IL, interleukin; a, alpha; b, beta; ra, receptor antagonist; TNF, 
tumor necrosis factor; NO, nitrous oxide; TNFR, tumor necrosis factor receptor; NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; GDNF, glial-derived neurotrophic 
factor; PTE, post-traumatic epilepsy; PTD, post-traumatic depression; PCA, principle component analysis.
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of sample collection varied as well, with the typical collection 
period of 5–7 days.
Numerous different panels of cytokines were evaluated within 
the CMD samples, across the studies included within the review. 
The most commonly studied cytokines included IL-1b, IL-1ra, 
IL-6, IL-8, and IL-10. Details of CMD technique and catheter 
locations are listed in Table 3.
CSF Cytokine Review
Sampling of CSF was conducted through external ventricular 
drains (EVDs) in almost all patients described within the studies 
included in the CSF cytokine systematic review (30–65). Sampling 
and analysis frequency varied significantly from study to study 
with sampling occurring from every 6  h to daily. Duration of 
sampling varied as well, up to 21 days post-injury (35).
TABLe 3 | CMD cytokine measures and outcomes.
Reference Catheter location and measured CMD 
cytokines
interventional 
therapies 
applied during 
measurement
Primary outcome Secondary 
outcome
Complications 
to CMD
Conclusions
Cederberg et al. (11) Mixed locations Not specified 6/7 patients survived N/A Not specified IL-6/IL-8 are increase in 
CDM both in “healthy” 
and peri-lesional tissue
IL-6/IL-8 IL-6 and IL-8 was increased in survivors
Unclear sampling interval [3 samples in each  
patient over course of intensive care unit (ICU) stay]
Peri-lesional location of CMD catheter yielded  
higher IL-6 and IL-8 levels
Perfusate not specified
Figaji et al. (12) Unclear locations Not specified Variable individual cytokine responses N/A Not specified IL-6/IL-8 are consistently 
increased in CMD in 
pediatric sTBI
IL-1a, IL-1b, IL1-ra, IL-6, IL-8, and IL-10; VEGF,  
and MCP-1
IL-6 and IL-8 were the most consistently elevated 
across all patients
Unclear sampling interval
Perfusate not specified
Guilfoyle et al. (13) 2× CMD catheters per patients  
(1 healthy tissue, 1 peri-lesional)
Not specified IL-7 (p < 0.05) and IL-8 (<0.05) were found to be 
higher in peri-lesional tissue
IL-1b and interferon gamma (INF-g) were higher in 
peri-lesional tissue within the first 72 h post-injury
N/A Not specified IL-7/IL-8 are higher in 
peri-lesional tissue
IL-1b and INF-g are 
higher in peri-lesional 
tissue within the first 72 h
“42 cytokines” IL-7 and IL-8
Unclear sampling interval
Perfusate not specified
aHelmy et al. (14) Area of “diffuse injury” Not specified IL-1b and TNF are covariate N/A Not specified PCA of CMD cytokine 
profiles yields covariate 
relationships between 
specific cytokines and 
temporal expression 
pattern
EGF, Eotaxin, FGF-2, fms-like tyrosine kinase 3  
(Flt3) lig, Frac, G-CSF, GM-CSF, GRO, IFN-a2, IFN-g, 
IL-1a, IL-1b, IL-1ra, IL-2, IL-3, IL-4, IL-5,  
IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-12p70, 
IL-13, IL-15, IL-17, inducible protein (IP)-10,  
MCP-1, MCP-3, MDC, MIP-1a, MIP-1b, PDGF-AA, 
PDGF-AAAB, regulated on activation, normal T cell 
expressed and secreted (RANTES), sCD40L,  
sIL-2R, TGF-a, TNF
IL-1ra and IL-1a are covariate
MIP-1a and MIP-1b were coexpressed
Earlier temporal expression of IL-6, GRO, G-CSF, 
IP10 compared to IL-10, MCP-3, IL-17
q6 h pooled sampling over 5 days
3.5% human ablumin solution perfusate
aHelmy et al. (15) Double side-by-side in six patients  
(to analyze perfusate), and single catheter  
in six patients—unclear tissue location
Unclear; two 
patients under 
went DC for 
refractory ICP
1. Albumin perfusate led to significantly higher 
fluid recovery compared to crystalloid. Albumin 
perfusate led to significantly higher cytokine 
recovery (18 cyotkines)
2. Brain concentrations of 23 cytokines were 
significantly higher than jugular plasma 
concentrations (ex. IL-1ra, IL-1a, IL-1b, IL-6,  
IL-8, IL-10, IL-12p70, MCP-1)
Many cytokines displayed a temporal expression, 
with expression within the first 72 h (e.g., TNF, 
IL-7, IL-8, MIP1a, sCD40L, IL-1β, GRO, PDGF, AA, 
RANTES, MIP-1b, IL-1ra, G-CSF, IP10, IL-6)
N/A Not specified 1. Ablumin CMD 
perfusate led to 
increased fluid and 
cytokine recovery
2. Brain cytokine 
concentrations were 
significantly higher 
than jugular plasma 
for 23 cytokines. 
Many cytokines 
displayed a temporal 
expression patter with 
early expression  
post-injury (72 h)
EGF, Eotaxin, FGF-2, Flt3 lig, Frac, G-CSF,  
GM-CSF, GRO, IFN-a2, IFN-g, IL-1a, IL-1b, IL-1ra, 
IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, 
IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IP-10, 
MCP-1, MCP-3, MDC, MIP-1a, MIP-1b, PDGF-AA, 
PDGF-AAAB, RANTES, sCD40L, sIL2R, TGFa, TNF
q6 h pooled sampling over 5 days
Assessed both crystalloid and 3.5% human  
albumin perfusate
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Reference Catheter location and measured CMD 
cytokines
interventional 
therapies 
applied during 
measurement
Primary outcome Secondary 
outcome
Complications 
to CMD
Conclusions
bHelmy et al. (16) Right frontal location (in setting of diffuse injury)
42 cytokine array
q6 h pooled sampling for 5 days
Isotonic central nervous system perfusate
Group 1 (n = 10): 
after baseline 6 h 
CMD samples; 
received 100 mg 
rhIL-1ra subcut
1. No complications secondary to rhIL-1ra were 
seen.
2. CMD IL-1ra concentrations were significantly 
higher in the treatment group vs. control 
(p = 0.02), with variation over time (p < 0.0001)
3. MDC was significantly lower in the rhIL-1ra 
(p = 0.05)
N/A Not specified 1. rhIL-1ra appears safe 
in severe diffuse TBI
2. rhIL-1ra reaches the 
brain extracellular fluid
3. MDC was lower in the 
rhIL-1ra groupRepeated q24 h 
for total of five 
doses
Group 2 (n = 10): 
control group
No specifics 
on other ICU 
therapies
bHelmy et al. (17) Right frontal location (in setting of diffuse injury)
42 cytokine array
q6 h pooled sampling for 5 days
3.5% human albumin perfusate
Group 1 (n = 10): 
after baseline 6 h 
CMD samples; 
received 100 mg 
rhIL-1ra subcut
Based on PCA it was found that cytokines 
associated with macrophage recruitment were 
decreased in the rhIL-1ra group (MIP-1a, MCP-3, 
Fractalkine, GM-CSF)
N/A Not specified CMD macrophage base 
cytokines are decreased 
in rhIL-1ra-treated 
patients
Repeated q24 h 
for total of five 
doses
Group 2 (n = 10): 
control group
No specifics 
on other ICU 
therapies
Hillman et al. (18) Paired CMD catheter placement in peri-lesional 
tissue
Not specified CMD IL-6 concentrations varied depending on 
underlying condition and secondary injury (i.e., 
ischemia)
N/A 1 catheter 
membrane failure
CMD IL-6 concentrations 
varied from patient to 
patient and depending 
on initial and secondary 
injury patterns
IL-6
q6 h pooled analysis The temporal expression of CMD measured IL-6 
varied between patientsRinger’s/dextran 60 or human albumin perfusate
Hillman et al. (19) Peri-lesional tissue
IL-1b, IL-6
q6 h pooled analysis
3.5% human albumin perfusate
Not specified CMD biochemical evidence of ischemia (LPR > 30 
and glutamate >80 μmol/L for 24 h period) was 
associated with significant IL-6 increase (p < 0.01), 
which subsided after ~90 h post-injury (p < 0.001)
N/A Not specified CMD IL-6 displays a 
correlation with CMD 
biochemical ischemia 
and a temporal 
correlation post-injury 
(in the absence of 
biochemical ischemia)
In those patients without biochemical ischemia, IL-6 
levels spiked in the first 48 h (p < 0.01)
IL-1b activation was less commonly observed (only 
53% of measures)
TABLe 3 | Continued
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Reference Catheter location and measured CMD 
cytokines
interventional 
therapies 
applied during 
measurement
Primary outcome Secondary 
outcome
Complications 
to CMD
Conclusions
Hutchinson et al. (20) Unclear tissue location (“frontal cortex”)
IL-1a, IL-1b, IL-1ra
q6 h pooled samples (mean no. samples = 9.1; 
range = 4–23)
Isotonic central nervous system perfusate
Not specified IL-1a and IL-1b concentrations were lower than 
IL-1ra
A positive correlation between IL-1ra and IL-1b was 
seen (p = 0.028)
No correlation between IL-1b and IL-1ra was found
No correlation between cytokines and CMD glucose, 
glutamate, LPR
ICP: ICP was 
negatively 
correlation 
to IL-1ra 
(p = 0.041)
Not specified 1. The appears to be a 
correlation between 
IL-1ra and IL-1b
2. There is a negative 
correlation between 
ICP and IL-1ra
3. Mean IL-1ra levels 
correlate to patient 
outcome at 6 months
No correlation 
between other 
cytokines and 
ICP
No correlation 
between 
cytokines and 
CPP
Outcome: 
significant 
relationship 
between 
mean IL-1ra 
levels and 
poor outcome 
(dichotomized 
GOS at 
6 months) 
(p = 0.018)—
high 
IL-1ra was 
associated 
with good 
outcome
No relationship 
between IL-1a 
and IL-1b with 
outcome
Mellergard et al. (21) Mixed locations; some patients with two catheters 
(unclear which patients)
Not specified IL-1b peaked in the first 12 h period
IL-6 peaked after 12 h post-insertion
IL-8 peaked within the first 6 h post-insertion
MIP-1b peaked within the first 6 h post-insertion
FGF-2 peaked within the first 6 h post-insertion
IL-10, VEGF, and RANTES did not show a temporal 
profile
N/A Not specified CMD catheter insertion 
leads to IL-1b/IL-6/
IL-8/MIP1b within the 
first 6–12 h, which 
then decrease during 
the subsequent time 
afterward
IL-1b, IL-6, IL-8, FGF-2, MIP-1b, RANTES, VEGF, 
IL-10
q6 h pooled samples for 36 h
Ringer-dextran 60 perfusate
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Reference Catheter location and measured CMD 
cytokines
interventional 
therapies 
applied during 
measurement
Primary outcome Secondary 
outcome
Complications 
to CMD
Conclusions
cMellergard et al. (22) Paired catheters (1 peri-lesonal; 1 healthy tissue)—
used the catheter with highest glycerol levels for 
measuring cytokines
Not specified; 
various surgical 
procedure for 
hemotomas in 
TBI group
IL-1b increased during the first 48 h, and then 
decreased
IL-6 increased over the first 48 h, and then 
decreased
IL-10 remained elevated throughout the 
measurement period
N/A Not specified IL-1b and IL-6 display a 
peak elevation during the 
first 48 h post-TBI
IL-10 remains elevated 
through the first 7 days 
post-TBI
IL-1b, IL-6, IL-10
q6 h pooled analysis for 7 days
Ringer-dextran 60 perfusate
cMellergard et al. (23) Paired catheters (1 peri-lesonal; 1 healthy tissue)—
used the catheter with highest glycerol levels for 
measuring cytokines
Not specified; 
various surgical 
procedure for 
hemotomas in 
TBI group
FGF-2 levels peaked at day 3 post-TBI
VEGF levels peaked on day 2 post-TBI
N/A Not specified FGF-2/VEGF levels 
peaked on days 3 and 2 
post-TBI
FGF-2, VEGF
q6 h pooled analysis for 7 days
Ringer-dextran 60 perfusate
Mellergard et al. (24) Unclear location
IL-1b, IL-6, IL-8, FGF-2, MIP-1b, RANTES, VEGF, 
IL-10
q6 h pooled sample analysis
Ringer-dextran 60 perfusate
Local protocols; 
not otherwise 
specified
IL-1b, IL-8, and IL-10 did not display age-related 
differences
N/A Not specified There may be an age-
related difference in the 
expression of VEGF, 
MIP-1b, RANTES, and 
FGF-2 post-TBI
VEGF, MIP-1b, and RANTES were different in the 
<25 years age group vs. over 25 years age
FGF-2 levels were significantly higher in the 
>65-year-old group (p < 0.0001)
Mondello et al. (25) Unclear location
IL-1b, IL-6, TNF-a, INF-g
Unclear sampling interval
Unclear perfusate
Not specified IL-6 showed high initial values that then decreased, 
in contrast IL-1beta, TNF-alpha and INF-gamma 
showed later elevations
N/A Not specified Variable cytokine 
temporal profiles are 
seen post-TBI
UCH-L1 levels negatively correlated (p < 0.05) with 
IL-1beta, widely used biomarker of inflammation
Parez-Barcena  
et al. (26)
Right frontal location; unclear tissue quality
IL-1b, IL-6, IL-8, IL10, IL-12, TNF-a
q8 h sample analysis (up to 248 h duration)
Isotonic central nervous system perfusate
Varied ICP/
CPP directed 
therapies; 
some use of 
barbiturates
IL-1b, IL-6, and IL-8 peaked during first 24 h 
post-injury
IL-10 remained unchanged during the sampling 
period
ICP: no 
correlation 
between 
IL-1b, IL-6, 
IL-8 and IL-10 
with ICP
Not specified  1. IL-1b, IL-6 and IL-8 
peaked within the first 
24 h post-injury
 2. No clear association 
was found between 
cytokines and ICP, 
PbtO2, CT changesPbtO2: 
no clear 
correlation 
between 
cytokines and 
PbtO2
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Reference Catheter location and measured CMD 
cytokines
interventional 
therapies 
applied during 
measurement
Primary outcome Secondary 
outcome
Complications 
to CMD
Conclusions
CT: no 
association 
found 
between 
cytokines and 
subsequent 
CT defined 
swelling or 
lesion change
Roberts et al. (27) Healthy tissue
IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and 
TNF-a
q6 h pooled analysis (up to 156 h of monitoring)
Isotonic central nervous system perfusate
Varied; one 
patient had DC
IL-1a, IL-1b, and TNF-a were elevated initially after 
injury
IL-6 and IL-8 were substantially higher in the CMD 
compared to other cytokines
IL-5 was barely detectable
Similar cytokine concentrations were seen in CSF 
and CMD, which were both substantially higher than 
jugular plasma sampled
Increase CMD concentrations of MMP-8 and MMP-
9 were seen with increases in the levels of IL-1a, 
IL-2, and IL-1a and -2 and TNF-a, respectively. In 
contrast, the CMD levels of MMP-7 decreased with 
increases in IL-1b, IL-2, and IL-6
Neuro Exam: 
IL-1b, IL-4 
and TNF-a 
levels were 
substantially 
higher in those 
with loss 
of pupillary 
reactivity
Not specified  1. IL-1a, IL-1b, TNF-a, 
IL-6 and IL-8 
predominate the 
cytokine response 
post TBI
 2. Various patterns of 
MMP changes are 
seen in correlation 
with changes in 
cytokine expression
 3. IL-1b, IL-4 and TNF-a 
levels were higher 
in those with loss of 
pupillary reactivity
 4. IL-6 and IL-8 
correlation with CPP. 
TNF-a correlations 
with ICP
ICP: IL-2 
displayed 
a negative 
correlation to 
ICP
TNF-a 
displayed 
a negative 
correlation to 
ICP
CPP: IL-6 and 
IL-8 displayed 
a negative 
correlation to 
CPP
PbtO2: no 
correlation 
found 
between 
cytokines and 
PbtO2
Outcome: no 
correlation 
between 
cytokines and 
GOS
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Reference Catheter location and measured CMD 
cytokines
interventional 
therapies 
applied during 
measurement
Primary outcome Secondary 
outcome
Complications 
to CMD
Conclusions
Winter et al. (28) Peri-lesional
IL-1b, IL-6, NGF
q3 h sampling (for 6 days)
Normal saline perfusate
Not specified CMD cytokine analysis is feasible and safe Peak cytokine 
levels were 
seen within 
the first 36 h 
post-injury
None  1. CMD cytokine 
analysis is feasible
 2. IL-1b may be the 
predominant CMD 
cytokine expressed
 3. Unclear patterns 
in survivors vs. 
non-survivors
IL-1b 
predominated 
with 
substantially 
higher 
concentrations 
compared to 
IL-6 and NGF
IL-6 was high 
in survivors, 
while NGF 
was lower in 
non-survivors
Winter et al. (29) Healthy tissue Not specified Higher IL-6 was seen in survivors (p = 0.04) N/A None IL-6 levels in CMD 
samples may correlation 
to survival and GOS at 
6 months
IL-1b, IL-6, NGF Peak IL-6 correlated to GOS at 6 months (p = 0.03)
q3 h sampling Peak NGF:IL-1b ratios were significantly lower in 
survivors (p = 0.01)Normal saline perfusate
TBI, traumatic brain injury; sTBI, severe TBI; GOS, Glasgow outcome scale; CMD, cerebral microdialysis; RCT, randomized control trial; ICP, intracranial pressure; CT, computed tomography; PbtO2, brain tissue oxygen monitoring; 
CPP, cerebral perfusion pressure; CSF, cerebrospinal fluid; LPR, lactate:pyruvate ratio; DC, decompressive craniectomy; μmol, micromolar; mm Hg, millimeters of mercury; L, liter; μmol, micromolar; IL, interleukin; a, alpha; b, beta; g, 
gamma; TNF, tumor necrosis factor; INF, interferon; MCP, monocyte chemoattractant protein; MIPs, macrophage inflammatory proteins; TGF, transforming growth factor; NGF, nerve growth factor; BDNF, brain-derived neurotrophic 
factor; GDNF, glial-derived neurotrophic factor; TNFR, tumor necrosis factor receptor; GM-CSF, granulocyte macrophage colony stimulating factor; sVCAM, soluble vascular cell adhesion molecule; sICAM, soluble intracellular adhesion 
molecule; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; MDC, macrophage-derived chemokine; FGFR, fibroblast growth factor receptor.
aSame patient population reported in both Helmy et al. (14) and Helmy et al. (15).
bSame patient population described in Helmy et al. (16) and Helmy et al. (17).
cSame patient population reported in both Mellergard et al. (22) and Mellergard et al. (23).
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TABLe 4 | CSF cytokine measures and outcomes.
Reference interval of cytokine 
measure
Measured CMD 
cytokines
interventional therapies 
applied during measurement
Outcome(s) of interest (patient outcome, 
neurophysiologic outcome, tissue outcome)
Other outcomes Conclusions
Abboud et al. (30) q12-h Intervals for 
5 days
IL-1α,IL-1β, IL-2, IL-4, 
IL-5, IL-6, IL-8, IL-10, 
IL-13, MIP-1a, MIP-
1b, TNF-a, VEGF
Not specified GOS at 6 and 12 months post-injury
Statistically significant differences in IL-4, IL-5, IL-6, 
IL-8, IL-13, and TNF-α (all p < 0.05) were observed 
between TBI survivors vs. non-survivors over 5 days
N/A Elevated IL-4, IL-6, IL-8, IL-23, 
and TNF-a levels may be 
associated with poor outcome 
at 6 and 12 months
Similarly, low IL-5 and IL-13 
may be associated with poor 
outcome
Bell et al. (31) q24-h Intervals for 
3 days
IL-6, IL-10 High variable; barbiturates 
and various ICP/CPP-directed 
therapies
Mortality (at unclear interval) IL-6 and IL-10 levels 
were increased 
compared to controls
Elevated IL-10 levels may be 
associated with mortalityIL-6 is not associated with mortality
Control group had 
banked CSF
IL-10 is associated with mortality (p = 0.022)
Chiaretti et al. (32) At 2 and 48 h 
post-injury
Controls were initially 
investigated for 
meningitis but were 
found to be negative. 
CSF was banked
IL-6, NGF Highly protocolized therapy; 
seemingly homogenous between 
patients
GOS at 6 months IL-6 and NGF were 
both elevated and 
increased between 
the two sampling 
periods
Lower IL-6 and NGF levels 
early post-TBI may be 
associated with better 
outcome at 6 months
Low IL-6 and NGF at 2 h post-injury was associated 
with good outcome (p < 0.01)
Increased IL-6 variation between the two time points 
was correlated with better outcome
IL-6 and NGF were 
positively correlated 
at both time periods
Chiaretti et al. (33) At 2 and 48 h 
post-injury
IL-1b, IL-6, NGF, 
BDNF, GDNF
Highly protocolized therapy; 
seemingly homogenous between 
patients
GOS at 6 months
Low NGF at 2 h (p < 0.01) and high NGF/IL-6 
(p = 0.02/p < 0.01) at 48 h were associated with 
better outcome
N/A Low initial NGF, followed by 
increased NGF/IL-6 may be 
associated with good outcome 
at 6 months
Low IL-1b at 48 h may 
be associated with better 
outcome at 6 months
Low IL-1b at 48 h was associated with better 
outcome (p < 0.01)
Chiaretti et al. (34) At 2 and 24 h 
post-injury
IL-1b and IL-6 Highly protocolized therapy; 
seemingly homogenous between 
patients
Dichotomized GOS at 6 months (good = 4 or 5; 
poor = 3 or less)
IL-1b and IL-6 at 2 h 
were higher in the TBI 
cohort
Elevated IL-1b and IL-6 at 
both 2 and 24 h post-injury 
may be associate with poor 
outcome at 6 months
Higher CSF IL-1b and IL-6 at both 2 h and 24 h 
were seen in those patients with poor outcome at 
6 months
Hans et al. (35) Daily CSF samples up 
to 21 days post-injury
IL-6 and sIL-6R Not specified Dichotomized GOS at 6 months (good = 4 or 5; 
poor = 3 or less)
CSF levels of IL-6 and 
sIL-6R were higher 
than compared to 
plasma
Elevated IL-6/sIL-6R may be 
associated with poor outcome 
at 6 monthsHigh IL6/sIL-6R was associated with poor outcome 
at 6 months
Hayakata et al. (36) 6, 12, 24, 48, 72, and 
96 h after injury
TNF-a, IL-1, IL-6, IL-8, 
and IL-10
Varied therapies; hypothermia 
and other ICP/CPP-directed 
approaches
Dichotomized GOS at 6 months (good = 4 or 5; 
poor = 3 or less)
CSF IL-1b was found to be higher in those with poor 
outcome
ICP: IL-1b was 
significantly positively 
correlated with ICP 
throughout the entire 
study (p < 0.05)
1. Elevated IL-1b may be 
associated with poor 
outcome at 6 months
2. Elevated IL-1b may be 
associated with elevated ICP
(Continued)
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Reference interval of cytokine 
measure
Measured CMD 
cytokines
interventional therapies 
applied during measurement
Outcome(s) of interest (patient outcome, 
neurophysiologic outcome, tissue outcome)
Other outcomes Conclusions
Various cytokine 
elevations were 
seen during S100B 
elevations. IL-1b 
peaks was correlated 
with S100B peak 
(p < 0.005)
Jamil et al. (37) Unclear interval; 
“acute” period 
post-TBI
IL-1b, IL-4, IL-5, 
IL-6, IL-7, IL-8, 
IL-10, IL-12, TNF-a, 
sICAM-1, sVCAM-1, 
sFAS
Not specified Patient health questionnaire (PHQ-9) at 6 and 
12 months post-injury
N/A 1. Elevated IL-6 and IL-8 
may be associate with 
depression at 6
2. TNF-a, IL-4, and IL-1b may 
be associated with lower 
chance of depression at 
12 months
Acute CSF IL-6 (p = 0.008), IL-8 (p = 0.034), 
and ICAM1 (p = 0.025) levels were higher among 
patients who would go on to develop depression 
6 months after injury
Acute CSF TNF-a (p = 0.036), IL-4 (p = 0.007), and 
IL-1b (p = 0.001) levels were individually associated 
with lower depression risk at 12 months post-injury
Juengst et al. (38) Within first week of 
injury
IL-4, IL-5, IL-8, IL-12, 
TNF-a, sVCAM, 
sICAM
Not specified Apathy subscale of the frontal systems behavior 
scale, collected at 6 and 12 months post-TBI
N/A Higher acute CSF IL5, sVCAM, 
and sICAM with apathy at 
6 months and lower acute 
serum TNFalpha, IL8, and IL5 
with apathy at 12 months
Higher acute CSF IL5, sVCAM, and sICAM with 
apathy at 6 months and lower acute serum 
TNFalpha, IL8, and IL5 with apathy at 12 months 
(p < 0.05)
Juengst et al. (39) 2 times daily for 
6 days
TNF-a Not specified At 6 and 12 months post-injury, FrSBe disinhibition 
subscale; suicidal endorsement was assessed by 
the PHQ-9
TBI patients had 
significantly higher 
CSF TNF-a levels 
compared to controls
Acute levels of TNF-a may 
correlate to 6 and 12 month 
rates of disinhibition
No relationship between TNF-a in CSF and  
suicidality at 6 or 12 months
Acute serum TNFa levels were inversely associated 
with 12-month disinhibition (r = 0.520, p = 0.027) 
and achieved borderline significance with 6-month 
disinhibition (r = 0.470, p = 0.057)
Juengst et al. (40) 2 times daily up to 
6 days
IL-1β, IL-4, IL-5, 
IL-6, IL-7, IL-8, 
IL-10, IL-12, TNF-a, 
sVCAM-1, sICAM-1, 
sFAS
Not specified PHQ-9 was administered to participants at 6 and 
12 months after injury
IL-1β, IL-4, IL-6, IL-7, 
IL-8, IL-10, TNF-α, 
sVCAM-1, sICAM-1, 
and sFAS (p < 0.05) 
were significantly 
elevated compared  
to controls
1. Elevated sVCAM-1, 
sICAM-1 and sFAS may 
be associated with PTD at 
6 months
2. Elevated IL-7 and IL-8 may 
be associated with PTD at 
12 months
The inflammatory cell surface markers sVCAM-1, 
sICAM-1, and sFAS in the CSF were each positively 
associated with PTD at 6 months (p < 0.02 for all 
comparisons).
The cytokine IL-8 was positively associated with 
PTD at 12 months (p < 0.02), while the cytokine IL-7 
was inversely associated with PTD at 12 months 
(p < 0.05)
Kirchhoff et al. (41) Upon EVD insertion, 
then at 12, 24, and 
48 h post-injury
IL-10 Not specified Mortality at unspecified interval
IL-10 was significantly higher in non-survivors
IL-10 was higher at all 
time points compared 
to non-TBI controls
Elevated CSF IL-10 at 
admission was associated 
with mortality
(Continued)
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Reference interval of cytokine 
measure
Measured CMD 
cytokines
interventional therapies 
applied during measurement
Outcome(s) of interest (patient outcome, 
neurophysiologic outcome, tissue outcome)
Other outcomes Conclusions
Control group: CSF 
gained from spinal 
anesthetics in elective 
non-TBI surgical 
cases
Kossmann  
et al. (42)
q24 h for unclear 
duration
Control group: non-
TBI patients (1 VPS 
and 2 Dx LP)
IL1b, IL-6, TNF-a, 
NGF
Various therapies; heterogeneous 
across population
Dichotomized GOS at 3 months (good = 4 or 5; 
poor = 3 or less)
IL-6 and NGF were 
high in TBI patients 
compared to control 
samples
NGF may be elevated in those 
with good outcome
High IL-6 levels were associated with NGF presence 
in CSF
NGF levels were elevated in those with better 
outcomes
Kumar et al. (43) 2 times daily for 
5 days
IL-6 Not specified Dichotomized GOS at 6 and 12 months (good = 4  
or 5; poor = 3 or less)
IL-6 levels were 
higher in TBI 
compared to controls
High IL-6 during the first 
5 days of injury may be 
associated with poor outcome 
at 6 months
Association between high IL-6 upon admission and 
6-month GOS (p = 0.003)
Kumar et al. (44) 2 times daily for up to 
5 days
IL-1β, IL-4, IL-5, 
IL-6, IL-7, IL-8, 
IL-10, IL-12, TNF-a, 
sVCAM-1, sICAM-1, 
sFAS
Not specified Trichotomized GOS at 6 and 12 months (good = 4 
or 5; poor = 3 or 2; dead = 1)
Cytokines were 
elevated in TBI 
patients compared to 
controls
Elevated IL-5, IL-6, IL-8, IL-10, 
sVCAM-1, and sICMA-1 
may be associated with poor 
outcome at 6 months
Individuals in cluster 1 (increased sICAM-1, sFAS, 
IL-10, IL-6, sVCAM-1, IL-5, and IL-8) had a 10.9 
times increased likelihood of GOS scores of 2/3 vs. 
4/5 at 6 months compared to cluster 2 (increased 
IL-12, IL7, IL-4)
Kushi et al. (45) Admission, 24, 72, 
and 168 h post-injury
IL-6, IL-8 High protocolized treatment; fairly 
homogeneous therapy
Mortality at unspecified interval N/A Elevated IL-6 and IL-8 during 
the first week post-TBI may be 
associated with mortality
IL-6 and IL-8 levels were significantly higher in CSF 
compared to serum
IL-6 and IL-8 levels were significantly higher in 
non-survivors
Nwachuku  
et al. (46)
q6 h for 5 days IL-1b, IL-6, TNF-a, 
IFN-a, IL-12p70, 
IL-10, and IL-8
Not specified Dichotomized GOS at 3, 6, 12, and 24 months 
(good = 4 or 5; poor = 3 or less)
N/A Elevated mean 5-day levels 
of various cytokines may be 
associated with poor outcome 
at 3, 6, 12, and 24 months 
post-injury
Mean 5-day levels of IFN-a, IL-10, IL-12 p70, IL-1, 
IL-6, IL-8, and TNF-a were associated with outcome 
(p < 0.05)
Santarseiri  
et al. (47)
2 times daily for up to 
6 days
IL-1β, IL-4, IL-5, 
IL-6, IL-7, IL-8, 
IL-10, IL-12, TNF-a, 
sVCAM-1, sICAM-1, 
sFAS
Not specified Dichotomized GOS at 6 months (good = 4 or 5; 
poor = 3 or less)
N/A Low mean IL-6, IL-8, IL-10, 
sICAM-1, and TNF-a may be 
associated with good outcome 
at 6 months post-injury
Cortisol: high cortisol patients were more likely to 
have elevated IL-10, IL-1b, IL-6, sFas, sICAM-1, 
sVCAM-1 and TNFa (p < 0.01 all comparisons, 
except IL-1b, p < 0.05) compared to low cortisol 
patients
Outcome: significant associations between GOS 
and mean levels of IL-10, IL-6, IL-8, sFas, sICAM-1 
(p < 0.01) and TNF-a (p < 0.05), with lower levels 
associated with favorable outcome
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cytokines
interventional therapies 
applied during measurement
Outcome(s) of interest (patient outcome, 
neurophysiologic outcome, tissue outcome)
Other outcomes Conclusions
Shiozaki et al. (48) q6 h for unclear 
duration
IL-1b, IL-1ra, IL10, 
TNF-a, sTNFr-I
Highly Protocolized therapy Dichotomized GOS at 6 months (good = 4 or 5; 
poor = 3 or less)
IL-1b, IL-1ra, sTNFr-I, 
and IL-10 were 
significantly higher 
in patients with high 
ICP than those with 
low ICP (p = 0.002, 
p = 0.006, p = 0.009, 
and p = 0.009, 
respectively). 
However, the CSF 
concentrations of 
TNF-a did not differ 
between patients with 
high ICP and those 
with low ICP
1. Elevated IL-lb, IL-1ra, 
IL-10, and sTNFr-I may 
be associated with poor 
outcome at 6 months
2. Elevated IL-1b, IL-1ra, 
IL-10, sTNFr-I may be 
associated with high ICP
IL-1b, IL-1ra, sTNFr-I, and IL-10 were significantly 
higher in patients with an unfavorable outcome than 
in patients with a favorable outcome (p = 0.006, 
p = 0.009, p = 0.003, and p = 0.012, respectively)
Singhal et al. (49) Unclear interval IL-1b, IL-6 Not specified SSEP: positive correlation between IL-6 and SSEP96 
(mean change in SSEP over 96 h) (p = 0.0133)
N/A 1. Elevated IL-6 may be 
positively correlated to 
SSEP over the first 96 h
2. Peak IL-6 levels may be 
associated with outcome at 
3 months
Outcome: GOS at 3 months
Peak IL-6 levels were associated with good outcome 
(p = 0.026)
Whalen et al. (50) Unclear sampling 
intervals
IL-8 Not specified Mortality at unspecified interval IL-8 levels were 
elevated compared to 
controls
Elevated IL-8 levels during 
the first week of injury may be 
associated with mortality
Elevated CSF IL-8 levels were associated with 
mortality (p = 0.01)
Neurophysiologic association
Muller et al. (51) Daily for 7 days IL-6, IL-8, IL-10 Not specified Transcranial doppler (TCD)-defined cerebral blood 
flow velocity
N/A Elevated IL-6 and IL-8 in the 
first 7 days may be negatively 
correlated to TCD defined 
MCBFV
Mean IL-6 and IL-8 level were significantly correlated 
to MCBFV (r = −0.341 and −0.361, respectively; 
p < 0.05)
Stein et al. (52) 2 times daily for 
7 days
IL-1b, IL-6, IL-8, 
IL-10, and TNF-a
High protocolized therapy ICP: negative association between early (within first 
12 h of injury) IL-6 and ICP (p = 0.004)
N/A 1. Elevated IL-6 within the 
first 12 h of injury may be 
associated with low ICP
2. Elevated IL-8 levels may be 
associated with low CPP
Positive correlation between time spent with CPP 
below 60 mm Hg and IL-8 levels (p = 0.001)
Outcome: dichotomized GOSE at 6 months 
(good = 5–8; poor = 1–4)
No association between CSF cytokines and outcome
Nil association studies
Amick et al. (53) Unclear time frame 
post-TBI (from 4 to 
122 h after injury)
IL-2, IL-4, IL-6, IL-12 Highly variable; barbiturates 
and various ICP/CPP-directed 
therapies
GOS at 6 months post-Injury IL-6 and IL-12 were 
increased compared 
to control group
No association between IL-2, 
IL-4, IL-6, and IL-12 with GOS 
at 6 months
TABLe 4 | Continued
(Continued)
18
Zeiler et al.
C
S
F and M
icrodialysis C
ytokines in TB
I
Frontiers in N
eurology | w
w
w
.frontiersin.org
July 2017 | Volum
e 8 | A
rticle 331
Reference interval of cytokine 
measure
Measured CMD 
cytokines
interventional therapies 
applied during measurement
Outcome(s) of interest (patient outcome, 
neurophysiologic outcome, tissue outcome)
Other outcomes Conclusions
Banked samples from 
a non-TBI control 
group (n = 12); 
CSF gained from 
investigations for 
meningitis
No correlation between measured CSF cytokines 
and GOS
Buttram et al. (54) Collected 18, 24, 48, 
and 72 h post-injury
IL-1a, IL-1b, IL-2, 
IL-4, IL-5, IL-6, IL-7, 
IL-8, IL-10, IL-12p70, 
IL-13, IL-15, IL-17, 
IP-10, eotaxin, TNF-a, 
INF-g, MCP-1, MIP-1a
Not well specified; half the groups 
was subjected to moderate 
hypothermia for 48 h (32–33°C)
Dichotomized GOS at 6 months Cytokine levels in 
TBI patients were 
significantly higher 
compared to controls
There is no association 
between CSF cytokines and 
outcome at 6 months
No association between CSF cytokines and outcome
Csuka et al. (55) Daily until EVD 
removal
IL-6, IL-10, TNF-a, 
TGF-B1
Unclear ICP/CPP-directed 
therapies
Outcome: GOS at 3–6 months
No correlation found between cytokines and 
outcome
ICP: no correlation between cytokines and ICP
IL-10 was found 
in both CSF and 
serum during the 
measurement period
CSF cytokines do not correlate 
to outcome at 3–6 months
CSF cytokines do not correlate 
to ICP
Diamond et al. (56) q12 h for 6 days IL1b Not specified EEG and Epileptologist defined PTE Serum IL-1b levels 
was associated with 
PTE
CSF IL-1b levels within the 
first week of injury is not 
associated with PTE
CSF IL-1b was not statistically associated with PTE
Goodman et al. (57) Unclear sampling 
interval
IL-1, IL-6, IL-8, IL-10, 
IL-12, TNF
Not specified ICP/CPP: no correlation between CSF cytokines and 
ICP or CPP
Serum and CSF IL-6 
and IL-8 were both 
elevated consistently
CSF cytokines are not 
associated with changes in 
ICP and CPP
Gopcevic et al. (58) Unclear sampling 
interval
IL-8 Not specified 30-day in-hospital mortality: no correlation between 
CSF IL-8 levels and patient outcome
No correlation 
between plasma and 
CSF IL-8 levels
CSF IL-8 is not associated 
with in-hospital mortality at 
1 month
Lenzlinger et al. (59) Daily for unclear 
duration
sIL-2R, B2M, 
neopterin
Unclear ICP direct therapy GOS at 4–6 months Neopterin levels were 
higher in CSF than 
serum
sIL-2R, B2M, and neopterin 
in CSF have no correlation to 
outcome at 4–6 months
No association between measured cytokines and 
outcome
B2M and sIL-2R levels 
were higher in serum
Maier et al. (60) Admission and daily 
up to day 10
sTNFRp55, 
sTNFRp75
Not specified GOS at 6 months sTNRFp55 and 
STNFRp75 is 
elevated in CSF 
compared to control
sTNFRp55 and sTNFRp75 
CSF levels are not associated 
with outcome at 6 months
No correlation between sTNFRp55 or sTNFRp75 
and outcome
Maier et al. (61) Admission and daily 
up to day 14
IL-6, IL-8, IL-10 Not specified Mortality at unspecified interval
No correlation between CSF cytokines and patient 
outcome
IL-6 and IL-8 were 
directly correlated with 
each other with CSF 
level higher than serum
CSF IL-6, IL-8, and IL-10 
levels do not correlated with 
mortality
All measured 
cytokines were 
higher in TBI patients 
compared to controls
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Like the CMD cytokine papers, the CSF cytokine papers 
included in this review reported the measurement of various 
cytokines. The most commonly measured cytokines in CSF 
reported were IL-1b, IL-1ra, IL-6, IL-8, IL-10, and TNF. The 
details of CSF sampling and specific cytokines measured can be 
found in Table 4.
Outcomes
CMD Cytokine Review
Given that the CMD cytokine portion of this review was a scop-
ing review of all the literature on CMD cytokines in sTBI, the 
goals and outcomes reported by the studies were heterogenous, 
and are listed in Table 3.
Only one study described an intervention during the 
assessment of CMD cytokines. This study was a prospective 
RCT describing the application of subcutaneous rhIL-1ra post 
severe diffuse TBI (16). The results described both elevated 
CMD IL-1ra levels and a reduction in MDC in the IL-1ra 
treated group. The follow-up retrospective statistical analysis 
of all CMD measured cytokines described a trend toward an 
increase in M1-microglia related cytokine activation following 
administration of rhIL-1ra (17).
Three studies reported the correlation between CMD cyto-
kines and patient outcome (11, 20, 29). Two studies reported a 
positive association between elevated CMD IL-6 and improved 
survival, with one describing improved Glasgow Outcome Scale 
(GOS) at 6 months (p = 0.03). One study reported the negative 
correlation between CMD IL-1ra and poor GOS at 6  months 
(p = 0.018).
Most studies reported the CMD cytokine profile post-TBI 
and temporal fluctuations (12, 14, 15, 21, 24, 26, 27). Given the 
myriad of cytokines measured across the studies, it is impossible 
to describe all of the relationships. Highlighted details can be 
found in Table  3. The main findings included elevated IL-1b, 
IL-6, and IL-8 within the first 48–72  h post-injury, with these 
cytokines also displaying peaks during these times (21–23). The 
CMD IL-10 levels were found to be more uniformly elevated 
during the sampling periods (22, 26). Finally, some coexpression 
relationships were found between IL-1b with TNF, IL-1ra with 
IL-1a, and MIP-1a with MIP-1b (14).
Two studies evaluated the CMD cytokine profile associated 
with secondary events while in the ICU (18, 19). CMD IL-6 levels 
were positively associated with episodes of ischemia/metabolic 
stress, as defined by a lactate:pyruvate ratio greater than 30 and 
glutamate levels greater than 80 μmol/L.
The relationship of catheter location to CMD cytokine levels 
was discussed in a couple of papers, with peri-lesional tissue 
displaying higher cytokine expressions than distant or healthy 
tissue locations (11, 13). Evaluation of catheter technology (18) 
and cytokine measure feasibility (28) were also described in a few 
studies.
CSF Cytokine Review
The 36 papers included in the CSF systematic review (30–65) 
included both manuscripts, which reported positive associations 
between CSF cytokine levels and neurophysiologic or patient 
outcome (30–52), and studies reporting no association (53–65) 
FigURe 1 | Flow diagram of search results for cerebral microdialysis review.
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(i.e., “nil association”) between CSF cytokines and the outcomes 
of interest for the CSF cytokine systematic review. No studies 
reported an association, “nil” or otherwise, between CSF cytokine 
measures and tissue outcome as assessed by follow-up neuro-
imaging. The subsections below describe more details of these 
outcomes of interest, with further information found in Table 4.
Positive Association Studies
Twenty-three papers included within the CSF cytokine review 
found associations between cytokine levels and both neurophysi-
ologic and patient outcomes. Twenty-one described the associa-
tion between CSF cytokines and patient outcome (30–50). Five 
papers discussed the association between CSF cytokine measures 
and neurophysiologic outcomes (36, 48, 49, 51, 52).
Patient Outcome. Cerebrospinal fluid levels of several cyto-
kines were related to functional patient outcomes. The most 
common outcomes specified were: overall mortality or GOS at 
6–12  months post-injury. The strongest relationships between 
cytokines and patient outcome were for IL-1b, IL-1ra, IL-6, IL-8, 
IL-10, and TNF.
A strong positive correlation between CSF measured IL-6 and 
IL-8 with poor GOS was the most commonly described relation 
between CSF cytokines and patient outcome (30, 32, 35, 36, 
42–47, 49, 50). Similarly, a strong association between elevated 
CSF measured IL-10 and poor patient outcome was described 
in five studies (31, 41, 46–48). Elevated CSF IL-1b was found to 
be associated with mortality and worse GOS at 6 months in four 
studies (33, 34, 36, 49). Finally, CSF TNF-alpha (TNF-a) levels 
were found to be associated with worse patient outcome in two 
studies (30, 46).
The relationship between CSF cytokine levels and neuropsy-
chiatric outcome was described in four studies (37–40). These 
associations included: higher IL-6 and IL-8 were associated with 
a higher incidence of depression at 6 months (37), TNF-a levels 
with depression at 12  months (37), IL-5/IL-8/IL-12/TBF with 
FigURe 2 | Flow diagram of search results for cerebrospinal fluid review.
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outcomes of interest (53–65). Eleven studies reported no asso-
ciation between various CSF cytokines and patient outcome, as 
reported by in-hospital mortality or GOS at 3–6 months (53–55, 
58–65). The cytokines reported within these studies varied sig-
nificantly, with the most common “nil associations” reported 
for IL-1b, IL-6, IL-8, IL-10, TNF-a, and sTNFR. A total of 376 
patients were described within these studies. Two studies reported 
no association between CSF cytokine measures and ICP/CPP 
(55, 57), while one study failed to determine an association between 
CSF IL-1b and post-traumatic epilepsy (56). Further detail on the 
“nil association” studies can be found at the bottom of Table 4.
Complications
Within the CMD cytokine manuscripts, the majority failed to 
report whether complications were considered within the data 
collection. Only three papers disclosed complication reporting 
(18, 28, 29), with two reporting “no complications” (28, 29), and 
apathy at 12 months (38), TNF-a with disinhibition at 12 months 
(39), and sVCAM/sICAM/sFAS with depression at 6 months (40).
Neurophysiologic Outcome. Three studies discussed the cor-
relation between CSF cytokine levels and ICP/CPP (36, 48, 52). 
Elevated IL-6 and IL-8 levels were associated with increased 
ICP and decreased CPP in one study (52). Elevated CSF IL-1b 
was associated with increased ICP in two studies (36, 48). One 
study found an association between CSF IL-6 and IL-8 levels and 
reduced middle cerebral artery (MCA) CBFV (51). Finally, one 
study found an association between IL-6 levels and the mean 
change in somatosensory evoked potential over 96 h recording 
window (49).
Nil Association Studies
Our review identified 13 studies documenting a “nil association” 
between CSF measured cytokines in sTBI patients and various 
23
Zeiler et al. CSF and Microdialysis Cytokines in TBI
Frontiers in Neurology | www.frontiersin.org July 2017 | Volume 8 | Article 331
one reporting a CMD catheter malfunction in one patient (19). 
The complication profiles may be under-reported within the 
CMD studies. Complication reporting within the CSF cytokine 
studies was essentially non-existent, with the focus of these stud-
ies the association between CSF cytokine measures and various 
outcomes.
DiSCUSSiON
CMD Cytokines in sTBi
Our scoping systematic review completed for CMD cytokine 
measures in sTBI allows limited conclusions. Despite 19 publi-
cations (11–29), this literature is based on very small numbers 
of patients with many studies conducted on the same patient 
populations with banked CMD samples. However, the limited 
conclusions are important. First, CMD-based measurement of 
cytokines is feasible. Second, CMD catheter location makes a 
difference in the levels of cytokines measured, with peri-lesional 
tissue producing high levels compared to distant or healthier 
tissue (11, 13). Third, peaks in CMD cytokine measures may 
occur within the first 48–72 h for IL-1b, IL-6, and IL-8 (21–23). 
Interestingly, IL-10 seems to remain elevated in CMD samples 
through the duration of the sampling periods described (22, 26). 
Fourth, IL-6 levels may prove to be predictive of ongoing second 
insults such as ischemia (18, 19). Fifth, the data from the rhIL-
1ra studies (16, 17) shows that subcutaneous rhIL-1ra leads to 
both an increase in CMD IL-1ra and a modulation of microglial/
macrophage based cytokine profiles. Sixth, CMD IL-1b/IL-1ra/
IL-6/IL-8 may be associated with poor outcome (11, 20, 29), up 
to 6 months post-injury. Finally, complications related to the use 
of CMD catheters are likely to be under-reported.
CSF Cytokines in sTBi
Our systematic review of CSF cytokines in sTBI, focused on the 
association between cytokine measures and patient, tissue out-
come, or neurophysiology outcomes identified some interesting 
trends. First, a large number of heterogeneous studies correlated 
CSF cytokine levels with patient outcome, defined as either 
mortality or GOS at 6–12  months post-injury. Various large 
panels of cytokines were described within these studies, but the 
strongest associations with outcome were found for IL-1b, IL-1ra, 
IL-6, IL-8, IL-10, and TNF. Most studies described an associa-
tion between elevated levels of these cytokines and poor GOS/
increased mortality. Second, psychiatric outcome at 6–12 months 
post-injury appears to have some association to CSF cytokine 
levels (37–40). Elevated CSF IL-6, IL-8, and TNF seem to have the 
strongest associations with depression, apathy, and disinhibition 
at 6–12  months. Third, analysis of the impact of CSF cytokine 
levels on neurophysiologic measures is limited, with only five 
studies documenting such data (36, 48, 49, 51, 52). The strongest 
relationship identified here was the link between elevated levels 
of various cytokines, such as IL-6 or IL-1b, and elevated ICP 
(36, 48, 52). Further work is required before robust conclusions 
can be drawn in this area. Fourth, none of the studies explored 
the link between CSF cytokine measures and tissue outcome, as 
assessed by follow-up neuroimaging. Fifth, despite the “positive” 
associations found in the previously described papers, 11 manu-
scripts found no relationship between CSF cytokines and patient 
outcome (53–55, 58–65). The patient numbers in the individual 
studies, which reported no associations was much smaller than 
that in the studies describing a positive association between CSF 
cytokines and patient outcome (mean of 28 vs. 41 patients/study, 
respectively), making lack of power a possible cause of a negative 
result. Further patients in the “nil association” studies represented 
an overall smaller sample, totaling 376 patients vs. 948 patients in 
the “positive association” studies. Finally, complication reporting 
within the CSF cytokine studies was absent. Selective reporting 
bias here is a major concern.
Limitations
Despite the interesting results of these two systematic reviews, 
there are significant study limitations, which need to be high-
lighted. Limitations with each separate review can be found 
within the subsections to follow.
CMD Cytokine Review
First, there were a small number of heterogenous studies found 
for the CMD review, with some manuscripts reporting on the 
same patient populations based on banked CMD samples. Most 
of these studies had patient cohort with unspecified heterogene-
ous patterns of injury in the setting of sTBI. The exceptions were 
the studies describing “diffuse” TBI patients only. These draw-
backs limit the generalizability of the results to all patients with 
sTBI. Second, the ICU and surgical therapies received by these 
patients during CMD sample collection/processing was quite 
heterogeneous and poorly reported, and could have driven sub-
stantial variation in CMD cytokine measures. Third, there were 
variations in CMD catheter location between studies. This could 
impact the CMD cytokine measures obtained and the described 
relationships. Fourth, complications association with CMD 
monitoring was seldom reported. We believe there is significant 
selective harms reporting. Finally, given the studies and results 
identified for the CMD review, there is likely a large publication 
bias, favoring only studies with positive results.
CSF Cytokine Review
First, there were many quite heterogeneous studies identified in 
the CSF cytokine review. The included papers varied by study 
design, number of patients, patient inclusion criteria, ICU-based 
therapies offered/provided to patients, blinding during outcome 
assessment, and primary outcome of the studies. Information 
regarding the relationship between CSF cytokine measures and 
patient outcome was often buried within the text, and often not 
an explicit target for the study. Furthermore, selective outcome 
reporting with regards to individual CSF cytokine measures and 
their association to patient outcome was present in many stud-
ies. Thus, the conclusions that can be drawn from these studies 
and the strength of associations between CSF cytokines with 
patient outcome/neurophysiologic outcome are limited. Second, 
selective outcome reporting was an issue in many studies with 
preference to reporting significant association(s) only, making 
no reference to other CSF measures and the results of statistical 
analysis. Third, complication reporting was concerning within 
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the literature identified (as mentioned above). Significant under-
reporting is suspected, with selective harms reporting the likely 
cause. Fourth, given all the above limitations and heterogeneity 
issues, a meta-analysis was not performed. Finally, though major-
ity of studies report a positive association between cytokine levels 
and outcome, given that this is an emerging area of research, it is 
important to consider whether this might represent a publication 
bias toward positive studies.
Correlation with Clinical Parameters
Several studies attempt to correlate a specific mediator concen-
tration with outcome. As these mediators are known to act in 
complex cascades and show a high degree of statistical collinear-
ity, simple inferences cannot be made about the role of a given 
mediator in causing a particular outcome or relating to a clinical 
parameter such as ICP. As these mediators are induced by the 
initial traumatic insult, they are all confounded by severity of 
injury: it is, therefore, not surprising that a high concentration of 
cytokine relates to a worsened clinical parameter. Furthermore, 
the timing of monitoring in relation to the time of injury is not 
consistently reported. Several mediators, such as IL6, can have 
differing biological effects depending on the milieu in which they 
are produced (68). Finally, many mediators are known to act in 
concert and regulate the same downstream pathways (e.g., IL1b 
and IL1ra) such that measuring a mediator in isolation does not 
reflect its true biological role, which is time and milieu dependent.
Future Directions
Given the significant heterogeneity in both study design, patient 
injury patterns, ICU/surgical treatments, and CMD/CSF cytokine 
measures identified within both systematic reviews, there is 
substantial room for more investigation into this emerging area 
of the literature in sTBI.
Although it is tempting to simply suggest that larger studies 
are done to overcome the heterogeneity in injury patterns follow-
ing TBI, there are significant limitations to this approach. There 
are an ever-expanding list of mediators available for analysis over 
multiple time points in a range of biological fluids and without a 
robust understanding of the interaction between these mediators, 
it is unlikely that a meaningful pattern will emerge through brute 
force of numbers. More refined approaches that explore within 
patient comparisons with multiple sites of monitoring (69), 
interventional studies in which specific modulation of a biologi-
cal pathway (16), and more sophisticated multivariate statistical 
methods (14).
Some studies have attempted to relate intensive care param-
eters such as ICP to the cytokine and chemokine response to 
TBI (26). This is not a simple relationship as the time frame 
over which cytokines and chemokines are produced occur over 
several days and weeks, rather than over the minutes and hours. 
There is insufficient evidence to stipulate, which intensive care 
interventions should be applied during monitoring of inflamma-
tory mediators; however, it is important for individual studies to 
report their intensive care protocols and interventions.
As CMD is necessarily focal in nature, strict reporting of the 
method of localization is required and ideally 2 catheter studies, 
1 in peri-lesional tissue and 1 in healthy tissue provides the most 
informative data (quote consensus paper).
When multiple mediators are measured, multivariate statisti-
cal methods must be employed, such as multivariate projection 
methods in order to model the potential interactions (14, 70).
This could potentially identify cytokine patterns of coexpres-
sion in CMD and CSF, highlighting target for future studies and 
therapeutic targets.
One deficit in the current CMD literature is complication 
reporting. In part, this relates to the difficulty in apportion-
ing complications to CMD catheter insertion specifically. As 
patients will have invasive monitoring for ICP monitoring and 
brain tissue oxygenation in any circumstance for directing 
clinical therapy, the additional risk of inserting CMD through 
an existing cranial access device is small and difficult to quan-
tify. Nevertheless, transparency dictates that complications are 
reported. Standardization of the methodologies employed allows 
multicenter prospective evaluation of cytokines within CDM and 
CSF and is necessary to improve patient recruitment and aid with 
spreading the substantial cost of cytokine analysis among cent-
ers. Without this collaboration, the limitations with single center 
recruitment and costs of cytokine processing in CMD and CSF 
limits the ability to combine datasets across units and studies. This 
would allow easier compilation of data sets and may add clarity 
to the associations highlighted within this manuscript. Finally, 
a consideration of the methodological factors that determine 
microdialysis catheter efficiency, including choice of perfusion 
fluid, catheter membrane, and pump flow rate all have an impact 
on the result obtained.
CONCLUSiON
The evaluation of CMD and CSF cytokines is an emerging area 
of the literature in sTBI. The two scoping systematic reviews have 
demonstrated a limited literature available on CMD cytokine 
measurement in sTBI, with some preliminary data supporting 
feasibility of measurement and associations between cytokines 
and patient outcome. Second, a number CSF cytokine levels may 
be associated with patient outcome at 6–12  months, including 
IL-1b, IL-1ra, IL-6, IL-8, IL-10, and TNF. Third, there is little to 
no literature to date in support of an association between CSF 
cytokines and neurophysiologic or tissue outcomes. Ultimately, 
the aim of CMD monitoring of inflammatory mediators is to 
reveal the underlying pathophysiology of TBI rather than as a 
clinical tool.
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